The cases were grouped according to two separate Ki-67 cut-off values (high: ≥14% and ≥20%, low
📌 3 Key Takeaways
🎯
Objective & Hypothesis:OBJECTIVE Immunohistochemical Ki-67 index is a useful method to determine the prognosis.
📊
Key Findings & Data:We aimed to evaluate the association of Ki-67 score, using 14% and 20% cut-off values, with clinicopathological parameters in invasive breast carcinomas.
💡
Conclusion & Impact:The cases were grouped according to two separate Ki-67 cut-off values (high: ≥14% and ≥20%, low
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
OBJECTIVE Immunohistochemical Ki-67 index is a useful method to determine the prognosis. We aimed to evaluate the association of Ki-67 score, using 14% and 20% cut-off values, with clinicopathological parameters in invasive breast carcinomas. METHODS Pathology reports of 162 females were retrospectively reviewed and parameters including age, menopausal status, multifocality/multicentricity (MF/MC), tumor size, histological type, grade, lymphovascular invasion (LVI), perineural invasion, axillary lymph node status, ER, PR, HER2 status, Ki-67 index, and molecular subtype were recorded. The cases were grouped according to two separate Ki-67 cut-off values (high: ≥14% and ≥20%, low
🔖
Cite This Article
İLVAN, Ş., ÖZTÜRK, T., DEMİR, H., GÜLLE, B. T. (2022). The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas. Türk Onkoloji Dergisi, Cilt: 36 - Sayı: 4, 415–422. https://ajindex.com/articles/639108
Penault-Llorca F, Radosevic-Robin N. Ki-67 assessment in breast cancer: An update. Pathology 2017;49(2):166–71
Ermiah E, Buhmeida A, Abdalla F, Khaled BR, Salem N, Pyrhönen S, et al. Prognostic value of proliferation markers: Immunohistochemical Ki-67 expression and cytometric s-phase fraction of women with breast cancer in Libya. J Cancer 2012;3:421–31
Haroon S, Hashmi AA, Khurshid A, Kanpurwala MA, Mujtuba S, Malik B, et al. Ki-67 index in breast cancer: Correlation with other prognostic markers and potential in Pakistani patients. Asian Pac J Cancer Prev 2013;14(7):4353–8
Aman NA, Doukoure B, Koffi KD, Koui BS, Traore ZC, Kouyate M, et al. Immunohistochemical evaluation of Ki-67 and comparison with clinicopathologic factors in breast carcinomas. Asian Pac J Cancer Prev 2019;20(1):73–9
Sun J, Chen C, Wei W, Zheng H, Yuan J, Tu YI, et al. Associations and indications of Ki-67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study. Oncol Lett. 2015;10(3):1741–8
Kamranzadeh H, Ardekani RM, Kasaeian A, Sadighi S, Maghsudi S, Jahanzad I, et al. Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: A retrospective cohort study. J Res Med Sci 2019;24:30
Elkablawy MA, Albasri AM, Mohammed RA, Hussainy AS, Nouh MM, Alhujaily AS. Ki-67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients. Saudi Med J 2016;37(2):137–41
Hortobagyi GN, Connolly JL, D’Orsi CJ, Edge SB, Mittendorf EA, Rugo HS, et al. Breast. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al, editors. AJCC Cancer Staging Manual. 8th ed. Switzerland: Springer International Publishing AG; 2017. p. 589–628
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO Classification of Tumours of the Breast. 4th ed. Lyon, France: IARC Press; 2012. 10.Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19(5):403– 10. 11.Fitzgibbons PL, Connolly JL. Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. CAP Guideline; 2021. Available at: https://www.documents.cap.org/ protocols/Breast.Bmk_1.4.1.0.REL_CAPCP.pdf. Accessed Aug 12, 2021. 12.Goldhirsch A, Wood WC, Coat